This is a working overview of Bremelanotide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-24 and is reviewed periodically as new material appears.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic melanocortin analogue |
| Molecular formula | C50H68N14O10 | Corresponds to a mass near 1025 daltons |
| Appearance | White to off-white powder | Lyophilised solid before reconstitution |
| Solubility | Soluble in water and polar solvents | Poor solubility in nonpolar media |
| Common synonyms | Bremelanotide, PT-141 | Code name and international name used interchangeably |
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
=== Social ties === In the article "Finding Happiness after Harvard", George Vaillant concluded a study on what aspects of life are important for "successful living". In the 1940s, Arlie Bock, while in charge of the Harvard Health Services, started a study, selecting 268 Harvard students from graduating classes of 1942, '43, and '44. He sought to identify the aspects of life contributing to "successful living". In 1967, the psychiatrist George Vaillant continued the study, undertaking follow-up interviews to gauge the lives of many of the students. In 2000, Vaillant again interviewed these students as to their progress in life. Vaillant observed: health, close relationships, and how participants dealt with their troubles. Vaillant found a key aspect to successful living is healthy and strong relationships. A widely publicized study from 2008 in the British Medical Journal reported happiness in social networks may spread from person to person. Researchers followed nearly 5000 individuals for 20 years in the long-standing Framingham Heart Study and found clusters of happiness and unhappiness that spread up to 3 degrees of separation on average. Happiness tended to spread through close relationships like friends, siblings, spouses, and next-door neighbors; researchers reported happiness spread more consistently than unhappiness through the network. Moreover, the structure of the social network appeared to affect happiness, as people who were very central (with many friends, and friends of friends) were significantly happier than those on the network periphery.
Whereas, wild type fungi are known to upregulate production of azole resistance drugs such as multidrug resistance protein 1 (MDR1) and transporters Cdr1 and Cdr2 that act like pumps to remove the antifungal drugs. Sphingolipid and sterols are the majority of the lipid bilayer membrane in fungi, e.g Candida species, and assist in formation of biofilms. Understanding the mechanism is utilized for development of vaccine adjuvants. Biofilm production is initiated through quorum sensing. Example of quorum sensing are the LuxR and LuxI proteins that attribute to the bioluminescence in Vibrio fischeri, LuxI produces acyl homoserine lactones (AHL) that are received by LuxR of neighboring bacteria, a specific concentration of AHL triggers gene expression of bioluminescence. Some vaccine adjuvants focus on biofilm formation by aiming to disrupt the communication utilizing current knowledge on quorum sensing.
== Post-playing career == On April 9, 2022, the Colorado Rockies hired Helton as a special assistant to the general manager, joining Vinny Castilla and Clint Hurdle in the role. They and Charlie Blackmon held that role in 2025.
The Centre Party (German: Zentrum, Z), officially the German Centre Party (German: Deutsche Zentrumspartei, DZP) and also known in English as the Catholic Centre Party, is a Christian democratic political party in Germany. It was most influential in the German Empire and Weimar Republic. Formed in 1870, it successfully battled the Kulturkampf waged by Chancellor Otto von Bismarck against the Catholic Church. It soon won a quarter of the seats in the Reichstag, and its middle position on most issues allowed it to play a decisive role in the formation of majorities. The party name Zentrum (Centre) originally came from the fact that Catholic representatives would take up the middle section of seats in parliament between the social democrats and the conservatives. For most of the Weimar Republic, the Centre Party was the third-largest party in the Reichstag and a bulwark of the Republic, participating in all governments until 1932. Following Adolf Hitler's rise to power in early 1933, the Centre Party was among the parties who voted for the Enabling Act, which granted legislative powers to Hitler's government. Nevertheless, the party was pressured into dissolving itself on 5 July, as the Nazi Party became the only legally permitted party in the country shortly thereafter. After World War II, the party was reconstituted, but could not rise again to its former importance, as most of its members joined the new interdenominational Christian Democratic Union (CDU) and, in Bavaria, the Christian Social Union (CSU).
=== Electron transfer reactions === Cytochrome P450 type enzymes that catalyze monooxygenase (hydroxylation) reactions are dependent on the transfer of two electrons from FAD to the P450. Two types of P450 systems are found in eukaryotes. The P450 systems that are located in the endoplasmic reticulum are dependent on a cytochrome P-450 reductase (CPR) that contains both an FAD and an FMN. The two electrons on reduced FAD (FADH2) are transferred one at a time to FMN and then a single electron is passed from FMN to the heme of the P450. The P450 systems that are located in the mitochondria are dependent on two electron transfer proteins: An FAD containing adrenodoxin reductase (AR) and a small iron-sulfur group containing protein named adrenodoxin. FAD is embedded in the FAD-binding domain of AR. The FAD of AR is reduced to FADH2 by transfer of two electrons from NADPH that binds in the NADP-binding domain of AR. The structure of this enzyme is highly conserved to maintain precisely the alignment of electron donor NADPH and acceptor FAD for efficient electron transfer. The two electrons in reduced FAD are transferred one a time to adrenodoxin which in turn donates the single electron to the heme group of the mitochondrial P450. The structures of the reductase of the microsomal versus reductase of the mitochondrial P450 systems are completely different and show no homology.
Sources: en.wikipedia.org
There was low- to moderate-strength evidence of no benefit for most of the other medications used in RCTs, which included antidepressants (bupropion, mirtazapine, sertraline), antipsychotics (aripiprazole), anticonvulsants (topiramate, baclofen, gabapentin), naltrexone, varenicline, citicoline, ondansetron, prometa, riluzole, atomoxetine, dextroamphetamine, and modafinil.
=== Metallocenophanes === Metallocenophanes feature linking of the cyclopentadienyl or polyarenyl rings by the introduction of one or more heteroannular bridges. Some of these compounds undergo thermal ring-opening polymerizations to give soluble high molecular weight polymers with transition metals in the polymer backbone. Ansa-metallocenes are derivatives of metallocenes with an intramolecular bridge between the two cyclopentadienyl rings.
== Veterinary use == The veterinary use of chlorpromazine has generally been superseded by the use of acepromazine. Chlorpromazine may be used as an antiemetic in dogs and cats, or, less often, as a sedative before anesthesia. In horses, it often causes ataxia and lethargy and is therefore seldom used. It is commonly used to decrease nausea in animals that are too young for other common antiemetics. It is sometimes used as a preanesthetic and muscle relaxant in cattle, swine, sheep, and goats. The use of chlorpromazine in food-producing animals is not permitted in the European Union, as a maximum residue limit could not be determined following assessment by the European Medicines Agency.
=== Sericin === Sericin is a group of water-soluble proteins that coat the fibroin filaments and bind them together within the cocoon. In suture manufacture and most biomaterial processing it is removed during a step called degumming, in part because early studies associated it with inflammation and allergic reactions. That association has since been re-examined, and purified sericin is used in its own right—in coatings, gels, cosmetics and pharmaceuticals—for its capacity to retain moisture and its antioxidant activity. Recovering sericin from silk-processing wastewater also makes use of a material that would otherwise be discarded.
Sources: en.wikipedia.org
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.
It is neither a steroid nor a naturally occurring human hormone. Bremelanotide is a manufactured peptide that mimics part of the melanocortin signalling system by binding receptor proteins. Its effects come from receptor activation, not from replacing a circulating hormone.
The internal lactam bridge locks the peptide into a defined shape, which raises receptor affinity and slows enzymatic breakdown. Linear versions of the same sequence are less stable and bind more weakly. Ring geometry is therefore central to how the molecule behaves in the body.
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.